Recursion Pharmaceuticals and AI Drug Discovery Skepticism

Cramer responds to a caller on Recursion, noting lack of proof of concept despite NVIDIA involvement and poor stock performance.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!